Newborn's fibrinolytic mechanism: Components and plasmin generation

Corrigan, James J.; Sleeth, Jeffrey J.; Jeter, Monette; Lox, Charles D.

doi:10.1002/ajh.2830320407

Cited by 89 publications

(64 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, prothrombotic factors account for two thirds of strokes in newborns and for >50% in infants and children, 79 and congenital heart malformations, vascular abnormalities, and infectious diseases are more frequent causes in children than in adults. 71 There are important physiological [80][81][82][83][84] Consequently, response to alteplase in neonates is impaired. Increasing doses of alteplase would not improve the response to thrombolysis but would be associated with an increase in the neonatal plasminogen concentration.…”

Section: Thrombolysis In the Pediatric Populationmentioning

confidence: 99%

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Demaerschalk¹,

Kleindorfer²,

Adeoye³

et al. 2016

Stroke

583

237

View full text Add to dashboard Cite

Purpose-To critically review and evaluate the science behind individual eligibility criteria (indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant tissue-type plasminogen activator (alteplase) treatment in acute ischemic stroke. This will allow us to better inform stroke providers of quantitative and qualitative risks associated with alteplase administration under selected commonly and uncommonly encountered clinical circumstances and to identify future research priorities concerning these eligibility criteria, which could potentially expand the safe and judicious use of alteplase and improve outcomes after stroke. Methods-Writing group members were nominated by the committee chair on the basis of their previous work in relevant topic areas and were approved by the American Heart Association Stroke Council's Scientific Statement Oversight Committee and the American Heart Association's Manuscript Oversight Committee. The writers used systematic literature reviews, references to published clinical and epidemiology studies, morbidity and mortality reports, clinical and public health guidelines, authoritative statements, personal files, and expert opinion to summarize existing evidence and to indicate gaps in current knowledge and, when appropriate, formulated recommendations using standard American Heart Association criteria. All members of the writing group had the opportunity to comment on and approved the final version of this document. The document underwent extensive American Heart Association internal peer review, Stroke The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on September 24, 2015, and the American Heart Association Executive Committee on October 5, 2015. A copy of the document is available at http://my.americanheart.org/statements by selecting either the "By Topic" link or the "By Publication Date" link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@ wolterskluwer.com.The online-only Data Supplement, which contains literature search strategies and Figures A, B, and C, is available with this article at http://circ. ahajournals.org/lookup/suppl/doi:10.1161/STR.0000000000000086/-/DC1.The American Heart Association requests that this document be cited as follows: Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; on behalf of the American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific rational...

show abstract

Section: Thrombolysis In the Pediatric Populationmentioning

confidence: 99%

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Demaerschalk¹,

Kleindorfer²,

Adeoye³

et al. 2016

Stroke

583

237

View full text Add to dashboard Cite

show abstract

“…[212][213][214] The decreased levels of plasminogen in newborns slows the generation of plasmin 215 and reduces the thrombolytic effects of streptokinase, urokinase and tissue plasminogen activator (tPA) in an in vitro fi brin clot system. 34 A similar response occurs in children with acquired plasminogen deficiency.…”

Section: Introductionmentioning

confidence: 99%

Antithrombotic Therapy in Neonates and Children

Monagle

Chan

Goldenberg

et al. 2012

Chest

1,268

559

View full text Add to dashboard Cite

“…It has been suggested that neonates are particularly prone to have such thrombotic complications as they have decreased levels of natural anticoagulants such as protein C, protein S, and antithrombin, as well as low levels of fibrinolytic components such as plasminogen [3].…”

Section: Discussionmentioning

confidence: 99%